CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC … – Nasdaq
|
CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR–T Therapies at SITC …
Nasdaq These data were presented during the Society for Immunotherapy in Cancer 32nd Annual Meeting during the Cellular Therapy Approaches Track poster session and a company-sponsored reception highlighting allogeneic CRISPR-based CAR–T cell therapy. |
